Francesco Galimi - Jan 24, 2024 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Role
SVP & Chief Medical Officer
Signature
/s/ Nick Harvey, Attorney-in-Fact
Stock symbol
ACET
Transactions as of
Jan 24, 2024
Transactions value $
-$11,897
Form type
4
Date filed
1/26/2024, 07:11 PM
Previous filing
Oct 3, 2023
Next filing
Jun 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACET Common Stock Tax liability -$11.9K -4.96K -6.16% $2.40 75.5K Jan 24, 2024 Direct F1
transaction ACET Common Stock Award $0 +26.3K +34.83% $0.00 102K Jan 24, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACET Stock Option (Right to Buy) Award $0 +288K $0.00 288K Jan 24, 2024 Common Stock 288K $2.40 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
F2 The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
F3 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.